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Tuberculosis and Legionella pneumophila
pneumonia in a patient receiving
anti-tumour necrosis factor-a (anti-TNF-a)
treatment
We read with interest the recent editorial in CMI
by Moiton et al. [1] concerning the impact of anti-
tumour necrosis factor (TNF)-a antagonists on the
emergence of infections. The recent introduction
into clinical practice of compounds that block
TNF-a has yielded great beneﬁts for patients
affected by selected autoimmune diseases that fail
to respond to classic anti-inﬂammatory agents.
Given the importance of TNF-a in the media-
tion of the host immune response, it is not
surprising that the use of TNF-a blockers leads
to increased susceptibility to infections. Most
reported infections concern the upper respiratory
and urinary tracts, and probably occur in the
setting of previous or concomitant immunosup-
pressive treatment. However, we would like to
stress that patients receiving anti-TNF-a antago-
nists are at high risk of developing infections
caused by intracellular pathogens, including
Mycobacterium tuberculosis, Coccidiodes immitis, Lis-
teria spp., Histoplasma capsulatum, Aspergillus spp.,
Nocardia spp. and Pneumocystis jiroveci [2–4]. To
illustrate the point, we would like to report the
case of a male, aged 30 years with Behcet disease,
who developed pulmonary tuberculosis and Leg-
ionella pneumophila pneumonia after anti-TNF-a
treatment with inﬂiximab.
The clinical history began in 1999, after the
development of recurrent oral aftosis, bilateral
epididimitis and uveitis. The patient underwent
ﬂuorangiography, which showed vasculitis, with
a positive Pathergy test and the presence of HLA-
B51. Local and systemic corticosteroid therapy,
and immunosuppressive therapy with cyclospo-
rin, methotrexate, interferon-a, clorambucil and
azatioprin were given; however, the various
therapeutic regimens were largely ineffective
and were associated with the occurrence of
side-effects. In 2003, the patient received an
infusion of inﬂiximab (5 mg ⁄ kg), followed by a
second infusion after a further 2 weeks. Two
weeks later, the patient developed pulmonary
tuberculosis; this was treated successfully with
speciﬁc antimicrobial chemotherapy, with com-
plete resolution of the clinical and radiological
symptoms. During 2003–2006, the patient
received immunosuppressive therapy and cycles
of leukocytoapheresis. In October 2006, following
recurrent bilateral uveitis, the patient received a
second infusion cycle of inﬂiximab (5 mg ⁄ kg), in
combination with methotrexate. Two weeks after
the second inﬂiximab infusion, the patient was
hospitalised with fever, dyspnoea, vomiting and
confusion, a temperature of 38C, a pulse-rate of
96 beats ⁄min, a respiratory rate of 24 breaths ⁄
min, and blood pressure of 140 ⁄ 80 mmHg. Clin-
ical examination revealed irregular heart activity,
diffuse bilateral rales on chest auscultation, and
abdominal pain. Laboratory ﬁndings were: hae-
moglobin, 13 g ⁄dL; white blood cells,
12 500 ⁄mm3 with 90% neutrophils; platelets,
175 000 ⁄mm3; C-protein, 67 mg ⁄L; Na+, 126 mm
Eq ⁄mL; pO2, 68 ⁄mmHg; liver and kidney func-
tion, normal. Chest imaging showed a left upper
lobe inﬁltrate and diffuse pleural thickening with
little pericardial effusion. Microbiological analyses
of blood and sputumwere negative forM. tubercu-
losis and other microorganisms, but L. pneumophila
serotype 1 antigen was detected in urine samples.
Antibiotic treatmentwith intravenous levoﬂoxacin
1000 mg daily and rifampicin 600 mg daily led to
an improvement of the clinical and radiological
symptoms and a complete resolution of the pneu-
monitis.
Patients affected by autoimmune inﬂammatory
rheumatic diseases are at increased risk of devel-
oping serious infections. Several determinants are
involved, including the wide range of immuno-
suppressive drugs administered to patients, the
severity of the underlying disease itself, the
presence of co-morbidities and, more recently,
the use of TNF-a blockers. Which of these deter-
minants is the main risk-factor remains unclear.
Infections caused by intracellular pathogens are a
major concern in patients receiving TNF-a antag-
onists. TNF-a is essential for the control and
containment of intracellular pathogens, as this
cytokine facilitates the recruitment of inﬂamma-
tory cells to the area of infection, stimulates the
formation and maintenance of granulomas, and
activates macrophages to kill pathogens. The
most common infection associated with the use
of TNF-a blockers is active tuberculosis [5]. In
recent years, screening strategies to identify and
treat latent tuberculous infection have reduced
the occurrence of anti-TNF-associated active
tuberculosis, whereas the role of screening for
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other intracellular pathogens, including L. pneu-
mophila, has not been established [6,7]. As sug-
gested by Moiton et al. [1], clinicians should
remain vigilant regarding patients treated with
TNF-a blockers in order to identify any infectious
events, especially those caused by intracellular
pathogens. Prompt notiﬁcation of such cases
should help to better deﬁne the impact of TNF-a
antagonists on the development of infections and
the effectiveness of preventive strategies.
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